# Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

> **NCT04620187** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 37 (estimated)

## Conditions studied

- Salivary Gland Cancer
- HER2 Gene Mutation

## Interventions

- **DRUG:** Ado-trastuzumab (T) emtansine (T-DM1)
- **RADIATION:** Standard of Care Radiotherapy
- **DRUG:** Standard of Care Chemotherapy

## Key facts

- **NCT ID:** NCT04620187
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-24
- **Primary completion:** 2028-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04620187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04620187, "Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04620187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*